Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intestinal microbiota and relapse after hematopoietic-cell transplantation
    Meeting Abstract

    Peled, J.; Devlin, S.; Staffas, A.; Lumish, M.; Rodriguez, K. P.; Ahr, K.; Perales, M.; Giralt, S.; Taur, Y.; Pamer, E.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients
    Meeting Abstract

    Zappasodi, R.; Li, Y.; Qi, J.; Wong, P.; Sirard, C.; Postow, M.; Newman, W.; Koon, H.; Velcheti, V.; Callahan, M. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • ImmunoMap: A novel bioinformatics tool for analysis of T cell receptor repertoire data in model systems and clinical settings
    Meeting Abstract

    Sidhom, J. W.; Bessell, C. A.; Havel, J.; Schneck, J.; Chan, T. A.; Sachsenmeier, E.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Exercise training reduces splenic accumulation of MDSCs and delays tumor progression in a therapeutic breast cancer model
    Meeting Abstract

    Wennerberg, E.; Schwitzer, E.; Lhuillier, C.; Koelwyn, G.; Hiner, R.; Jones, L.; Demaria, S.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
    Meeting Abstract

    Leidner, R.; Kang, H.; Haddad, R.; Segal, N. H.; Wirth, L. J.; Ferris, R. L.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T. F.; Sharfman, W.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study
    Meeting Abstract

    Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Keynote-045: Open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures
    Journal Article

    Yu, A. F.; Jones, L. W.
    Cardio-Oncology (2016)

    Fulltext@MSK | Save
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
    Journal Article

    McNeel, D. G.; Bander, N. H.; Beer, T. M.; Drake, C. G.; Fong, L.; Harrelson, S.; Kantoff, P. W.; Madan, R. A.; Oh, W. K.; Peace, D. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save